We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (219)
- Scheduling (national classification system) (59)
- Manufacturing (28)
- Advertising (22)
- Unique Device Identification (UDI) hub (21)
- Safety monitoring and information (17)
- Compliance and enforcement (15)
- Clinical trials (10)
- Vaping hub (9)
- Legislation (8)
- Medicinal cannabis hub (5)
- Shortages and supply disruptions (3)
- Breast implant hub (2)
- Cosmetics (1)
- Import and export (1)
- Labelling and packaging (1)
Search
465 result(s) found, displaying 126 to 150
-
WebinarsUDI Webinar 16 – Australian UDI update and guest speakers on the value of UDI for procurement and inventory management in hospitals.
-
Committee meetingsThe 3rd meeting of the Women's Health Product Working Group (WHPWG #3), March 2023
-
PresentationsThe TGA Good Manufacturing Practice Forum returned to Sydney on 21 March 2023.
-
PresentationsThis webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be conditionally classified as Schedule 8 (controlled drug) in the Poisons Standard.
-
WebinarsThis webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) when prescribed by a psychiatrist.
-
WebinarsIn this webinar we will provide an update on the Australian UDI implementation and discuss the challenges and benefits of having UDI in healthcare and the role of hospitals and other healthcare providers in relation to using UDI.
-
-
Committee meetingsAdvisory Committee on Medical Devices (ACMD) meeting
-
-
PresentationsThis webinar will explain labelling requirements for finished MCP in detail.
-
Committee meetingsThe 2nd meeting of the Women's Health Product Working Group (WHPWG #2), October 2022
-
-
PresentationsThis webinar will guide you through the process of charging for regulatory activities, the medicinal cannabis funding model and the fees and charges structure and amounts proposed to commence on 1 July 2023.
-
WebinarsThe final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.
-
PresentationsThe final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.
-
Committee meetingsAdvisory Committee on Medical Devices (ACMD) meeting
-
WebinarsThis webinar will focus on how the changes under the EU MDR will affect manufacturer evidence and variations to the ARTG.
-
WebinarsChanges to the formatting and structure of the Poisons Standard will come into effect from 1 February 2023
-
PresentationsThis is the second in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR, with a focus on manufacturer evidence and variations to the ARTG.
-
PresentationsPresentation on the new formatting and structure of the Poisons Standard
-
WebinarsThis webinar will outline what regulatory actions are required as a result of changes under the EU MDR, and how the TGA will streamline the transition.
-
PresentationsThis is the first in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR.
-
Committee meetingsTherapeutic Goods Advertising Consultative Committee
-
-
WebinarsThe purpose of this webinar was to help sponsors understand how to use the Listed Medicines Evidence Guidelines to compile a robust evidence package that supports the efficacy of their listed medicine.